Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 2Diagnosis: Brain/Neuro Cancer: Other Non-Glioblastoma, Breast: MetastaticNCT ID: NCT00496379
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 06-268
The purpose of this research study is to determine the effects (good and bad) of ZK219477(sagopilone) on participants and their cancer. ZK219477 is a chemotherapy drug that is thought to work by interfering with the ability of cancer cells to grow and divide. It is a part of a group of drugs called "epothilones" which appear to cause shrinkage of cancer in some patients with breast cancer. It is generally difficult for chemotherapy to enter the brain. However, it is believed that ZK219477 crosses into the brain. We are also studying whether an investigational MRI scan procedure may eventually help to predict which patients will benefit from ZK219477.
Conducting Institutions: Dana-Farber Cancer Institute, Beth-Israel Deaconess Medical Center, Brigham and Women's Hospital
Overall PI: Nancy Lin, MD,
Dana-Farber Cancer Institute
Site-responsible Investigators: Steven Come, MD,
Beth Israel Deaconess Medical Center
Contacts: Dana-Farber Cancer Institute:
Breast Cancer Nursing Team, 617-632-3478Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060